Skip to content

US · DMAC · BIOTECHNOLOGY

DiaMedica Therapeutics Inc. (DMAC) intrinsic value and stock valuation

$8.25as of 2026-11-21 · Mkt cap 359.13M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

DiaMedica Therapeutics Inc. DCF and intrinsic value

InvestorsCraft values DMAC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from DMAC’s statements →

DiaMedica Therapeutics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Minneapolis, MN 55305 diamedica.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-32.77M
20112025
Free cash flow
-$-29.1M
20112025
Total equity
$56.1M+16.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-34.4M-$-26.68M-$-21.27M-$-14M-$-13.65M
Net income-$-32.77M-$-24.44M-$-19.38M-$-13.68M-$-13.59M
EPSd-$-697.53K-$-604.95K-$-595.03K-$-517.4K-$-654.31K
Operating cash flow-$-29.06M-$-22.08M-$-18.73M-$-11.51M-$-12.25M
Capital expenditure-$-40K-$-30K-$-20K-$-80K-$-20K
Free cash flow-$-29.1M-$-22.1M-$-18.75M-$-11.59M-$-12.27M
Total assets$61.4M$46.3M$54.2M$34.4M$45.6M
Total debt$240K$340K$400K$470K$50K
Net debt-$-15.41M-$-2.69M-$-4.14M-$-4.26M-$-4.66M
Total equity$56.1M$40.7M$51.1M$31.8M$44M
Cash and short-term investments$59.9M$44.2M$52.9M$33.5M$45.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$24.6M$19.1M$13.1M$7.84M$8.77M
Selling, general and administrative expenses$9.78M$7.62M$8.16M$6.16M$4.88M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$34.4M$26.7M$21.3M$14M$13.7M
Cost and expenses$34.4M$26.7M$21.3M$14M$13.7M
Interest income$0.00$2.3M$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$40K$40K$30K$30K$20K
Ebitda-$-32.7M-$-24.38M-$-19.31M-$-13.62M-$-13.54M
Operating income-$-34.4M-$-26.68M-$-21.27M-$-14M-$-13.65M
Total other income/expenses, net$1.66M$2.27M$1.93M$350K$80K
Income before tax-$-32.74M-$-24.41M-$-19.34M-$-13.65M-$-13.56M
Income tax expense$30K$30K$40K$30K$30K
Net income-$-32.77M-$-24.44M-$-19.38M-$-13.68M-$-13.59M
Weighted average shares outstanding$47M$40.4M$32.6M$26.4M$20.8M
Weighted average diluted shares outstanding$47M$40.4M$32.6M$26.4M$20.8M
Balance sheet
20252024202320222021
Cash and short-term investments$59.9M$44.2M$52.9M$33.5M$45.1M
Net receivables$260K$240K$370K$80K$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$60.6M$44.6M$53.7M$33.8M$45.4M
Property, plant and equipment, net$340K$430K$480K$560K$110K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$740K$1.74M$480K$560K$110K
Total assets$61.4M$46.3M$54.2M$34.4M$45.6M
Accounts payable$1.48M$940K$930K$730K$510K
Short-term debt$110K$100K$80K$70K$50K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$5.13M$5.39M$2.79M$2.17M$1.52M
Long-term debt$130K$240K$320K$400K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$130K$240K$320K$400K$0.00
Capital lease obligations$240K$340K$400K$470K$50K
Total liabilities$5.26M$5.63M$3.1M$2.57M$1.53M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-172.77M-$-140M-$-115.56M-$-96.18M-$-82.5M
Accumulated other comprehensive income (loss)$50K$20K$10K-$-70K-$-50K
Total equity$56.1M$40.7M$51.1M$31.8M$44M
Total investments$44.2M$41.1M$48.4M$28.8M$40.4M
Total debt$240K$340K$400K$470K$50K
Net debt-$-15.41M-$-2.69M-$-4.14M-$-4.26M-$-4.66M
Cash flow statement
20252024202320222021
Net income-$-32.77M-$-24.44M-$-19.38M-$-13.68M-$-13.59M
Depreciation and amortization-$-900K$40K$30K$30K$20K
Stock-based compensation$3.85M$2.08M$1.68M$1.5M$1.56M
Change in working capital$680K$1.51M$90K$580K-$-460K
Accounts receivable-$-20K$130K-$-290K$50K$210K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$540K$10K$190K$230K-$-590K
Net cash provided by operating activities-$-29.06M-$-22.08M-$-18.73M-$-11.51M-$-12.25M
Investments in property, plant and equipment-$-40K-$-30K-$-20K-$-80K-$-20K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-2.19M$8.56M-$-18.3M$11.5M-$-20.54M
Common stock issued$44.3M$11.8M$36.9M$0.00$29.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$43.9M$12M$36.8M-$-10K$30.1M
Net change in cash$12.6M-$-1.52M-$-180K$20K-$-2.7M
Cash at end of period$15.7M$3.02M$4.54M$4.73M$4.71M
Operating cash flow-$-29.06M-$-22.08M-$-18.73M-$-11.51M-$-12.25M
Capital expenditure-$-40K-$-30K-$-20K-$-80K-$-20K
Free cash flow-$-29.1M-$-22.1M-$-18.75M-$-11.59M-$-12.27M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About DiaMedica Therapeutics Inc.

        DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.

        CEO
        Dietrich John Pauls
        Employees
        35
        Beta
        0.97

        Explore

        Frequently asked questions

        What is the intrinsic value of DiaMedica Therapeutics Inc. (DMAC)?

        InvestorsCraft does not currently publish an intrinsic value for DMAC. How the IC value is calculated.

        Is DMAC undervalued?

        InvestorsCraft does not publish an undervaluation signal for DMAC at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.